Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Empagliflozin feasibility study in idiopathic pulmonary arterial hypertension
NL-OMON51825Phase 2Completed
- Sponsor
- Amsterdam University Medical Center
- Start
- Mar 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of empagliflozin in Plexogenic Pulmonary Arteriopathy, sponsored by Amsterdam University Medical Center. Started Mar 2023; status: completed.
02
Drugs
empagliflozin
03
Conditions
Plexogenic Pulmonary Arteriopathy
Beyond the preview
Go deeper on NL-OMON51825.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON51825.